Vol. 6 No. 5 (2026): May
Reimbursement Reviews

Ribociclib (Kisqali)

decorative image of the issue cover

Published May 25, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses ribociclib (Kisqali), 200 mg, tablets, oral.
  • Indication: In combination with an aromatase inhibitor for the adjuvant treatment of adult patients with HR-positive, HER2-negative stage II-III early breast cancer at high risk of recurrence. In pre- or perimenopausal women, or men, the aromatase inhibitor should be combined with a luteinizing hormone–releasing hormone agonist.